Melinda J Gooderham1,2, Chih-Ho Hong2,3, Lorne Albrecht2,4, Robert Bissonnette5, Gurbir Dhadwal2,6, Robert Gniadecki7, Parbeer Grewal2,7,8, Mark G Kirchhof9, Ian Landells10, Perla Lansang11,12, Chuck W Lynde2,13, Kim A Papp2,14, Yves Poulin15, Gordon Sussman16, Irina Turchin17, Marni Wiseman18, Jensen Yeung2,11,12,19. 1. 1 SKiN Centre for Dermatology, Peterborough, ON, Canada. 2. 2 Probity Medical Research, Waterloo, ON, Canada. 3. 3 Dr. Chih-ho Hong Medical, Inc, Surrey, BC, Canada. 4. 4 Enverus Medical, Surrey, BC, Canada. 5. 5 Innovaderm Research, Montréal, QC, Canada. 6. 6 Dr. Gurbir Dhadwal, MD, Inc, Vancouver, BC, Canada. 7. 7 Division of Dermatology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. 8. 8 Stratica Medical Centre for Dermatology, Edmonton, AB, Canada. 9. 9 Division of Dermatology, Department of Medicine, University of Ottawa and The Ottawa Hospital, Ottawa, ON, Canada. 10. 10 Nexus Clinical Research, St John's, NL, Canada. 11. 11 Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 12. 12 Division of Dermatology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 13. 13 Lynde Institute for Dermatology, Markham, ON, Canada. 14. 14 K Papp Clinical Research, Waterloo, ON, Canada. 15. 15 Centre de Recherche Dermatologique du Québec Métropolitain, Quebec City, QC, Canada. 16. 16 Sussman Allergy, Toronto, ON, Canada. 17. 17 Brunswick Dermatology Centre, Fredericton, NB, Canada. 18. 18 Skinwise Dermatology, Winnipeg, MB, Canada. 19. 19 Division of Dermatology, Women's College Hospital, Toronto, ON, Canada.
Abstract
BACKGROUND: : Atopic dermatitis (AD) is a chronic, relapsing, and remitting inflammatory skin disease with complex pathophysiology, primarily driven by type 2 inflammation. Existing guidelines often do not reflect all current therapeutic options and guidance on the practical management of patients with AD is lacking. OBJECTIVES: : To develop practical, up-to-date guidance on the assessment and management of adult patients with AD. METHODS: : An expert panel of 17 Canadian experts, including 16 dermatologists and 1 allergist, with extensive clinical experience managing moderate-to-severe AD reviewed the available literature from the past 5 years using a defined list of key search terms. This literature, along with clinical expertise and opinion, was used to draft concise, clinically relevant reviews of the current literature. Based on these reviews, experts developed and voted on recommendations and statements to reflect the practical management of adult patients with AD as a guide for health care providers in Canada and across the globe, using a prespecified agreement cutoff of 75%. RESULTS: : Eleven consensus statements were approved by the expert panel and reflected 4 key domains: pathophysiology, assessment, comorbidities, and treatment. CONCLUSIONS: : These statements aim to provide a framework for the assessment and management of adult patients with AD and to guide health care providers in practically relevant aspects of patient management.
BACKGROUND: : Atopic dermatitis (AD) is a chronic, relapsing, and remitting inflammatory skin disease with complex pathophysiology, primarily driven by type 2 inflammation. Existing guidelines often do not reflect all current therapeutic options and guidance on the practical management of patients with AD is lacking. OBJECTIVES: : To develop practical, up-to-date guidance on the assessment and management of adult patients with AD. METHODS: : An expert panel of 17 Canadian experts, including 16 dermatologists and 1 allergist, with extensive clinical experience managing moderate-to-severe AD reviewed the available literature from the past 5 years using a defined list of key search terms. This literature, along with clinical expertise and opinion, was used to draft concise, clinically relevant reviews of the current literature. Based on these reviews, experts developed and voted on recommendations and statements to reflect the practical management of adult patients with AD as a guide for health care providers in Canada and across the globe, using a prespecified agreement cutoff of 75%. RESULTS: : Eleven consensus statements were approved by the expert panel and reflected 4 key domains: pathophysiology, assessment, comorbidities, and treatment. CONCLUSIONS: : These statements aim to provide a framework for the assessment and management of adult patients with AD and to guide health care providers in practically relevant aspects of patient management.
Authors: Jung Eun Kim; Min Kyung Shin; Gyeong-Hun Park; Un Ha Lee; Ji Hyun Lee; Tae-Young Han; Hyun Chang Koh; Yong Hyun Jang; Hye One Kim; Chan Ho Na; Bark-Lynn Lew; Ji Young Ahn; Chang Ook Park; Young Joon Seo; Yang Won Lee; Sang Wook Sohn; Young Lip Park Journal: Ann Dermatol Date: 2019-10-31 Impact factor: 1.444
Authors: Bernd W M Arents; Esther J van Zuuren; Sofieke Vermeulen; Jan W Schoones; Zbys Fedorowicz Journal: Br J Dermatol Date: 2022-05 Impact factor: 11.113